PF-AtlasКлинические испытания › NCT03522831

CF Bronchodilation

Salbutamol · Не указано

ID реестра
NCT03522831
Фаза
Не указано
Статус
Активно, набор закрыт
Препарат / вмешательство
Salbutamol
Спонсор
University of British Columbia
Начало
2018-05-01
Набор участников
20
Центры
1

Об исследовании

It is estimated that one in every 3,600 children in Canada has cystic fibrosis (CF). CF is a genetic disease that affects the glands that produce mucus and sweat. In CF, mucus production increases and the mucus becomes thick and sticky. This can block the airways, making it difficult to breathe. Mucus production also causes bacteria to grow, which can lead to infections in the lungs. Individuals with CF suffer from shortness of breath, wheezing, cough, and poor exercise capacity. There are limited treatment options to reduce shortness of breath in these individuals. Some medications known as bronchodilators are commonly prescribed to reduce breathlessness in patients with CF. These drugs help open the airways making it easier to breathe. Unfortunately, there is limited scientific proof that these drugs can reduce shortness of breath and improve exercise capacity in patients with CF. As a result, some experts have recommended that these drugs should not be prescribed for patients with CF. The purpose of this study is to examine the effects of a bronchodilator on shortness of breath, exercise performance, and breathing responses compared to a placebo drug in adults with CF.

Открыть NCT03522831 на ClinicalTrials.gov →

Связанные материалы

Связанные исследования

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT03522831 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.